Effects of human and experimental cancer on the conversion of 14C tripalmitin to 14CO2
- PMID: 953967
- DOI: 10.1002/1097-0142(197609)38:3<1259::aid-cncr2820380328>3.0.co;2-m
Effects of human and experimental cancer on the conversion of 14C tripalmitin to 14CO2
Abstract
14C Tripalmitin was administered intraperitoneally to control mice and to mice bearing subcutaneous Krebs-2 carcinoma. The rate of excretion of 14CO2 was studied. The presence of a tumor induced a greater than 80% suppression of the formation of 14CO2 within 24 hours from the implantation of the tumor, thus allowing unambiguous identification of the tumor-bearing mice. When cancer patients were studied, along with normal volunteers and patients with non-neoplastic diseases, 14CO2 excretion data could be used to identify the cancer patients with an overall accuracy of 84%.